Thalidomide Prevents Formation of Multinucleated Giant Cells (Langhans-Type Cells) from Cultured Monocytes: Possible Pharmaceutical Applications for Granulomatous Disorders
Free accessResearch articleFirst published online July, 2009
Thalidomide Prevents Formation of Multinucleated Giant Cells (Langhans-Type Cells) from Cultured Monocytes: Possible Pharmaceutical Applications for Granulomatous Disorders
Thalidomide is an effective drug for chronic inflammatory diseases, but the mechanism underlying its immunomodulatory action remains uncertain. Thalidomide has been reported to clinically improve chronic inflammatory granulomatous disorders. In such disorders, the granulomas consist of epithelioid cells, scattered lymphocytes and multinucleated giant cells (MNGC; Langhans-type cells). The present experimental approach permitted the reproduction of MNGC formation from peripheral blood monocytes and examination of thalidomide's effect on it. MNGC can be effectively generated from monocytes cultured in the presence of interleukin-4 (IL-4) and macrophage colony-stimulating factor (M-CSF) for 14 days. Thalidomide can inhibit the formation of MNGC in a dose-dependent manner. MNGC formation was partly inhibited by the presence of neutralizing TNF-α antibody in the responses induced by IL-4 and M-CSF. Autocrinal TNF-α production and modulation of cadhelin expression to regulate cell adhesion might be involved in this inhibitory action of thalidomide. Our results support thalidomide's clinical efficacy in the treatment of chronic granulomatous disorders (granulomatosis).
LehmanTJASchechterSJSundelRPOliveiraSKHuttenlocherAOnelKB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr2004; 145:856–7.
7.
KaplanGThomasSFiererDS. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses2000; 16:1345–55.
8.
CattelanAMTrevenzoliMAversaSM. Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol2002; 3:451–62.
9.
BessisDGuillotBMonpointSDandurandMGuihouJJ. Thalidomide for systemic lupus erythematosus. Lancet1992; 339:549–50.
10.
SchoemanJFSpringerPRavenscroftADonaldPRBekkerLGvan RensburgAJHanekomWAHaslettPAKaplanG. Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role. J Child Neurol2000; 15:497–503.
11.
GinsburgPMHananIEhrenpreisED. Treatment of severe esophageal Crohn's disease with thalidomide. Am J Gastroenterol2001; 96:1305–6.
12.
YasuiKMisawaYShimizuTKomiyamaAKawakamiTMizoguchiM. Thalidomide therapy for juvenile-onset entero-Behçet disease. J Pediatr2003; 143:692–4.
13.
YasuiKUchidaNAkazawaYNakamuraSMinamiIAmanoYYamazakiT. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis2008; 14:396–400.
14.
CarlesimoMGiustiniSRossiABonaccorsiPCalvieriS. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol1995; 32:866–9.
15.
BaughmanRPJudsonMATeirsteinASMollerDRLowerEE. Thalidomide for chronic sarcoidosis. Chest2002; 122:227–32.
16.
OliverSJKikuchiTKreugerJGKaplanG. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol2002; 102:225–36.
17.
SampaioEPSarnoENGalillyRCohnZAKaplanG. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med1991; 173:699–703.
18.
MarriottJBWestbyMDalgleishAG., The therapeutic potential of TNF-α inhibitors old and new. Drug Discov Today1997; 2:273–82.
19.
ToroJRChuPBen-YenTLeBoitPE. Granuloma annulare and human immunodeficiency virus infection. Arch Dermatol1999; 135:1341–6.
20.
PuissegurMPLayGGilleronM. Mycobacterial lipomannan induces granulomamacrophage fusion via a TLR2-dependent, ADAM9- and β1 integrin-mediated pathway. J Immunol2007; 178:3161–9.
21.
LemaireIYangHLauzonWGendronN. M-CSF and GM-CSF promote alveolar macrophage differentiation into multinucleated giant cells with distinct phenotypes. J Leukoc Biol1996; 60:509–18.
22.
MiyamotoTOhnedaOAraiFIwamotoKOkadaSTakagiKAndersonDMSudaT. Bifurcation of osteoclasts and dendritic cells from progenitors. Blood2001; 98:2544–54.
23.
Strauss-AyaliDConradSMMosserDM. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol2007; 82:244–52.
24.
NomuraKKurodaSYoshikawaHTomitaT. Inflammatory osteoclastogenesis can be induced by GM-CSF and activated under TNF immunity. Biochem Biophys Res Commun2008; 367:881–7.
25.
McInnesARennickDA. Interleukin 4 induces cultured monocyte-macrophages to form giant multinucleated cells. J Exp Med1988; 167:598–611.
26.
McNallyAKAndersonJM. Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Am J Pathol1995; 147:1487–99.
27.
McNallyAKAndersonJM. Foreign body-type multinucleated giant cell formation is potently induced by α-tocopherol and prevented by the diacylglycerol kinase inhibitor R59022. Am J Pathol2003; 163:1147–56.
28.
SetsukinaiKUranoYKakinumaKMajimaHJNaganoT. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem2003; 278:3170–5.
29.
FerreroDPessanoSPagliardiGLRoveraG. Induction of differentiation of human myeloid leukemias: Surface changes probed with monoclonal antibodies. Blood1983; 61:171–9.
30.
CollinsSJRuscettiFWGallagherREGalloRC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethylsufoxide and other polar compounds. Proc Natl Acad Sci USA1979; 75:2458–62.
31.
LinJHYangXBostromPG. Thalidomide blocking of particle-induced TNFα release in vitro. J Orthop Sci2003; 8:79–83.
32.
LokensgardJRHuSvan FenemaEMShengWSPetersonPK. Effect of thalidomide on chemokine production by human microglia. J Infect Dis2000; 182:983–7.
33.
CorralLGHaslettPAMullerGWChenRWongLMOcampoCJ. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α. J Immunol1999; 163:380–6.
34.
MorenoJLMikhailenkoITondraviMMKeeganAD. IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: Contribution of E-cadherin. J Leukoc Biol2007; 82:1542–53.
35.
MajumdarSLamotheBAggarwalBB. Thalidomide suppreses NF-κB activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharide, or phorbol ester. J Immunol2002; 168:2644–51.
36.
GockelHRLügeringAHeidemannJSchmidtMDomschkeWKucharzikTLügeringN. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol2004; 172:5103–9.
37.
OsborneGEMallonEMayouSC. Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol2003; 48(S):99–102.
